Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Etemadi, Arash ^a,b   Kamangar, Farin ^c   Islami, Farhad ^a,d   Poustchi, Hossein ^e   Pourshams, Akram ^e   Brennan, Paul ^f   Boffetta, Paolo ^g   Malekzadeh, Reza ^a   Dawsey, Sanford M ^b   Abnet, Christian C ^b   Emadi, Ashkan ^h  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MORGAN STATE UNIVERSITY   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

Author keywords

ABO; Blood group; Cancer; Cardiovascular disease; Mortality; Rh

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; OPIATE; BLOOD CLOTTING FACTOR 8; BLOOD GROUP ABO SYSTEM; VON WILLEBRAND ANTIGEN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD GROUP ABO SYSTEM; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CAUSE SPECIFIC SURVIVAL; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; SMOKING; SOCIAL STATUS; STOMACH CANCER; INCIDENCE; MIDDLE AGED; MORTALITY; NEOPLASM; PROPORTIONAL HAZARDS MODEL; RISK; SOCIAL CLASS;

ABO BLOOD-GROUP SYSTEM; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FACTOR VIII; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RISK; SMOKING; SOCIAL CLASS; VON WILLEBRAND FACTOR;

EID: 84922982318     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-014-0237-8     Document Type: Article

References (35)

1. Garratty G: Blood groups and disease: a historical perspective. Transfus Med Rev 2000, 14:291-301.
2. Jenkins PV, O'Donnell JS: ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006, 46:1836-1844.
3. Cserti CM, Dzik WH: The ABO blood group system and Plasmodium falciparum malaria. Blood 2007, 110:2250-2258.
4. Sharara AI, Abdul-Baki H, ElHajj I, Kreidieh N, Kfoury Baz EM: Association of gastroduodenal disease phenotype with ABO blood group and Helicobacter pylori virulence-specific serotypes. Dig Liver Dis 2006, 38:829-833.
5. Yamamoto F, Cid E, Yamamoto M, Blancher A: ABO research in the modern era of genomics. Transfus Med Rev 2012, 26:103-118.
6. Liumbruno GM, Franchini M: Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus 2013, 11:491-499.
7. He M, Wolpin B, Rexrode K, Manson JE, Rimm E, Hu FB, Qi L: ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol 2012, 32:2314-2320.
8. Franchini M, Mannucci PM: ABO blood group and thrombotic vascular disease. Thromb Haemost 2014, in press.
9. Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB: ABO blood group and cancer. Eur J Cancer 2010, 46:3345-3350.
10. Liumbruno GM, Franchini M: Hemostasis, cancer, and ABO blood group: the most recent evidence of association. J Thromb Thrombolysis 2014, 38:160-166.
11. Nakao M, Matsuo K, Ito H, Shitara K, Hosono S, Watanabe M, Ito S, Sawaki A, Iida S, Sato S, Yatabe Y, Yamao K, Ueda R, Tajima K, Hamajima N, Tanaka H: ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infection. Cancer Epidemiol Biomarkers Prev 2011, 20:1665-1672.
12. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, Jafari E, Rakhshani N, Salahi R, Semnani S, Kamangar F, Abnet CC, Ponder B, Day N, Dawsey SM, Boffetta P, Malekzadeh R: Cohort profile: The Golestan Cohort Study-a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol 2010, 39:52-59.
13. Khademi H, Etemadi A, Kamangar F, Nouraie M, Shakeri R, Abaie B, Pourshams A, Bagheri M, Hooshyar A, Islami F, Abnet CC, Pharoah P, Brennan P, Boffetta P, Dawsey SM, Malekzadeh R: Verbal autopsy: reliability and validity estimates for causes of death in the Golestan Cohort Study in Iran. PLoS One 2010, 5:e11183.
14. Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Abedi-Ardekani B, Merat S, Nasseri-Moghaddam S, Semnani S, Sepehr A, Wakefield J, Møller H, Abnet CC, Dawsey SM, Boffetta P, Malekzadeh R: Socio-economic status and oesophageal cancer: results from a population-based case-control study in a high-risk area. Int J Epidemiol 2009, 38:978-988.
15. Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, Abaie B, Islami F, Nasseri-Moghaddam S, Etemadi A, Byrnes G, Abnet CC, Dawsey SM, Day NE, Pharoah PD, Boffetta P, Brennan P, Kamangar F: Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ 2012, 344:e2502.
16. Hanley JA: A heuristic approach to the formulas for population attributable fraction. J Epidemiol Community Health 2001, 55:508-514.
17. Wu O, Bayoumi N, Vickers MA, Clark P: ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008, 6:62-69.
18. Carpeggiani C, Coceani M, Landi P, Michelassi C, L'Abbate A: ABO blood group alleles: a risk factor for coronary artery disease. An angiographic study. Atherosclerosis 2010, 211:461-466.
19. Cesena FH, da Luz PL: ABO blood group and precocity of coronary artery disease. Thromb Res 2006, 117:401-402.
20. Ketch TR, Turner SJ, Sacrinty MT, Lingle KC, Applegate RJ, Kutcher MA, Sane DC: ABO blood types: influence on infarct size, procedural characteristics and prognosis. Thromb Res 2008, 123:200-205.
21. Garrison RJ, Havlik RJ, Harris RB, Feinleib M, Kannel WB, Padgett SJ: ABO blood group and cardiovacular disease: the Framingham study. Atherosclerosis 1976, 25:311-318.
22. Amirzadegan A, Salarifar M, Sadeghian S, Davoodi G, Darabian C, Goodarzynejad H: Correlation between ABO blood groups, major risk factors, and coronary artery disease. Int J Cardiol 2006, 110:256-258.
23. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, et al: Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
24. Chen Y, Chen C, Ke X, Xiong L, Shi Y, Li J, Tan X, Ye S: Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease. Circ Cardiovasc Genet 2014, 7:43-48.
25. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Myocardial Infarction Genetics Consortium, Wellcome Trust Case Control Consortium, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, et al: Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011, 377:383-392.
26. Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, Mateo J, Madoz P, Stone W, Blangero J, Fontcuberta J: Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000, 20:2024-2028.
27. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999, 19:3071-3078.
28. Gandhi C, Ahmad A, Wilson KM, Chauhan AK: ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. J Thromb Haemost 2014, 12:255-260.
29. van Schie MC, van Loon JE, de Maat MP, Leebeek FW: Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost 2011, 9:899-908.
30. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332:635-641.
31. Tregouet DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika D, Juhan-Vague I, Alessi MC, Tiret L, Lathrop M, Emmerich J, Morange PE: Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009, 113:5298-5303.
32. Heit JA, Armasu SM, Asmann YW, Cunningham JM, Matsumoto ME, Petterson TM, De Andrade M: A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J Thromb Haemost 2012, 10:1521-1531.
33. Yamamoto F, McNeill PD, Hakomori S: Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 1992, 187:366-374.
34. Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M, Nyren O: Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010, 172:1280-1285.
35. Forouzanfar MH, Sepanlou SG, Shahraz S, Dicker D, Naghavi P, Pourmalek F, Mokdad A, Lozano R, Vos T, Asadi-Lari M, Sayyari AA, Murray CJ, Naghavi M: Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Arch Iran Med 2014, 17:304-320.